Frovatriptan Succinate - CAS 158930-09-7
Catalog number: 158930-09-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H23N3O5
Molecular Weight:
361.40
COA:
Inquire
Targets:
5-HT Receptor
Description:
Thesuccinate salt form of Frovatriptan, a carbazole derivative, has been found to be a 5-HT receptor agonist that could be used as an antimigraine agent.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Powder
Synonyms:
Frovatriptan succinate; (3R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide butanedioate;1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3R)-, butanedioate (1:1);Sb-209509ax;Vml 251
Storage:
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
MSDS:
Inquire
Quality Standard:
In-house standard
Quantity:
Milligram-Grams
InChIKey:
WHTHWNUUXINXHN-SBSPUUFOSA-N
InChI:
InChI=1S/C14H17N3O.C4H6O4/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13;5-3(6)1-2-4(7)8/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18);1-2H2,(H,5,6)(H,7,8)/t9-;/m1./s1
Canonical SMILES:
CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N.C(CC(=O)O)C(=O)O
1.[Frovatriptan possibly causing acute myocardial infarction].
Møller-Helgestad OK1, Kaltoft AK, Kasch H. Ugeskr Laeger. 2015 Mar 23;177(13):V10140537.
Globally migraine affects more than 10% of the adult population and it is treated with simple analgesics, combined with a triptan for a stronger treatment effect. Triptans cause arterial vasoconstriction, and this is a case report of vasospasm-induced acute myocardial infarction in a 61-year-old woman with frequent episodic migraine attacks treated with triptans. She was possibly also suffering from medication overuse headache. We suggest that regular frovatriptan use may have contributed to the myocardial infarction and that long-term triptan use may have caused the medication overuse headache.
2.Variability of the characteristics of a migraine attack within patients.
Viana M1, Sances G2, Ghiotto N2, Guaschino E2, Allena M2, Nappi G2, Goadsby PJ3, Tassorelli C4. Cephalalgia. 2015 Oct 23. pii: 0333102415613612. [Epub ahead of print]
BACKGROUND: Migraine attacks may present different features in different patients and also within the same patient. The percentage of patients reporting stereotyped attacks and those reporting attacks with different phenotypes has not been the object of specific investigations.
3.Factors associated with frovatriptan response in patients with migraine: A prospective, observational study.
Seo JG1, Park SP2. Cephalalgia. 2015 Jul 13. pii: 0333102415596443. [Epub ahead of print]
BACKGROUND: Almost one-third of patients with migraine do not adequately respond to triptans. We examined factors contributing to frovatriptan response in patients with migraine.
4.The therapeutic armamentarium in migraine is quite elderly.
Martelletti P1. Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):175-7. doi: 10.1517/17425255.2015.982089. Epub 2014 Dec 1.
Global Burden of Disease 2010 study considers migraine as one of the most important noncommunicable diseases in the world, classifying it third in terms of global prevalence (14.70%): it sums up the 54.19% of all the years of life lived with disabilities caused by the rest of all neurological disorders. This Editorial provides an historical excursus of old and new-entry molecules in migraine therapeutic area. Drugs for acute treatment such as triptans date back to the early 1990s with the appearance of sumatriptan and the following six triptans in the years immediately after (zolmitriptan, rizatriptan, naratriptan, eletriptan, almotriptan, frovatriptan). Prophylaxis drugs, dedicated to patients with medium/high frequency of crises, show as last entries topiramate and botulinum toxin type A. The use of this preventative group, with its intrinsic limits, is mandatory to reduce the risk of migraine chronification, a highly harmful clinical phenomenon that produces as its natural consequence the medication overuse headache.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related 5-HT Receptor Products


CAS 189188-57-6 Tegaserod maleate

Tegaserod maleate
(CAS: 189188-57-6)

Tegaserod maleate is a partial agonist of the 5-HT4 receptor (Ki = 12 nM) that can treat irritable bowel syndrome (IBS).

CAS 158876-82-5 Rupatadine

Rupatadine
(CAS: 158876-82-5)

Rupatadine, with the potential to treat allergic rhinitis and urticaria, is a potent and long-lasting dual antagonist of PAF/H1. in vitro: Without affecting con...

CAS 256227-77-7 GMC 2-113

GMC 2-113
(CAS: 256227-77-7)

GMC 2-113 is a selective 5-HT1B antagonist.

CAS 183140-97-8 GMC 1-169

GMC 1-169
(CAS: 183140-97-8)

GMC 1-169 is an atypical antipsychotic devoid of muscarinic activity.

Aripiprazole lauroxil
(CAS: 1259305-29-7)

Aripiprazole lauroxil is a Dopamine D2 receptor agonist, Serotonin 1A receptor agonist and ISerotonin 2A receptor antagonist under the development of Alkermes p...

Asenapine hydrochloride
(CAS: 1412458-61-7)

Asenapine hydrochloride, also called Org 5222 and HSDB 8061, shows high affinity for numerous receptors including 5-HT receptor and adrenergic receptor. (pKi: 5...

Mirisetron maleate
(CAS: 148611-75-0)

Mirisetron maleate, an oxoquinoline derivative, has been found to be a 5-HT3 receptor antagonist that could probably be effective against anxiety disorders and ...

CAS 103639-04-9 Ondansetron Hydrochloride Dihydrate

Ondansetron Hydrochloride Dihydrate
(CAS: 103639-04-9)

Ondansetron hydrochloride dihydrate is a specific and competitive antagonist of serotonin 5-HT3 receptor (Ki = 0.77 nM) with anxiolytic and neuroleptic activiti...

CAS 148672-15-5 GMC 2-29

GMC 2-29
(CAS: 148672-15-5)

GMC 2-29 is a potent and selective 5-HT1B/1D antagonist.

CAS 78095-20-2 (S)-(-)-8-Hydroxy-DPAT hydrobromide

(S)-(-)-8-Hydroxy-DPAT hydrobromide
(CAS: 78095-20-2)

A 5-HT1A receptor partial agonist that is less active compared to R-(+)-8-hydroxy-DPAT.

CAS 135722-25-7 S 14506

S 14506
(CAS: 135722-25-7)

S 14506 is a potent and selective 5-HT1A agonist.

CAS 223699-41-0 p-MPPF dihydrochloride

p-MPPF dihydrochloride
(CAS: 223699-41-0)

p-MPPF dihydrochloride is a selective 5-HT1A antagonist.

CAS 179474-81-8 Prucalopride

Prucalopride
(CAS: 179474-81-8)

Prucalopride is a potent and selective 5-HT4 receptor agonist. Prucalopride is a gastroprokinetic drug with the brand name Resolor, developed for the treatment ...

CAS 161611-99-0 DU125530

DU125530
(CAS: 161611-99-0)

DU125530 is a selective 5-HT1A receptor antagonist (Ki = 0.7 nM). DU125530 has the potential to be used in the treatment of anxiety, depression and psychiatric ...

SB-269970
(CAS: 201038-74-6)

SB-269970 is a selective 5-HT7 receptor antagonist (pKi of 8.3) with >50-fold selectivity against other receptors, on amphetamine and ketamine-induced hyperacti...

BRL 15572
(CAS: 734517-40-9)

BRL-15,572 is selective 5-HT1D antagonist with around 60x selectivity over other related receptors. It is a useful tool for the differentiation between human 5-...

CAS 844903-58-8 GSK163090

GSK163090
(CAS: 844903-58-8)

GSK163090 is Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.

CAS 706779-91-1 Pimavanserin

Pimavanserin
(CAS: 706779-91-1)

Pimavanserin is a potent and selective 5-HT2A receptor inverse agonist used in the treatment of Parkinson’s disease psychosis.

CAS 109889-09-0 Granisetron

Granisetron
(CAS: 109889-09-0)

Granisetron is an antagonist of serptpmom 5-HT3 receptor and could be used to relieve the nausea and vomiting symptom after receving chemotherapy by decreasing ...

CAS 866933-46-2 Velusetrag

Velusetrag
(CAS: 866933-46-2)

Velusetrag is a selective, 5-HT4receptor agonist. Phase II clinical trials for the treatment of gastroparesis are on-going. Clnical trials for Alzheimer's disea...

Chemical Structure

CAS 158930-09-7 Frovatriptan Succinate

Quick Inquiry

Verification code

Featured Items